drugset / Trial / NCT00157079

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079

Phase 3 Completed 61 enrolled Baxalta now part of Shire
RandomizedCrossoverTreatment

Summary

The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.

Timeline

Start
2002-06-25
Primary completion
2003-12-16
Completion
2003-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 10 % Intravenous